Cord blood red cell concentrates for preterm neonate transfusion: Insights from the multicenter BORN trial.
Обработка статьи · этапы, ошибки и управление
Ошибки и ограничения
История · было → стало
Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.
Pellegrino Claudio, Papacci Patrizia, Dani Carlo, Cresi Francesco, Remaschi Giulia, Ansaldi Giulia, Giannantonio Carmen, Campagnoli Maria Francesca, Vania Barbara, Fabbri Marco, Aragona Roberta Penta de Vera d', Molisso Anna, Beccastrini Enrico, Dragonetti Antonella, Pasciuto Tina, Gabbriellini Sabrina, Baroni Silvia, Serrao Francesca, Purcaro Velia, Raffaeli Genny, Villa Stefania, Prati Daniele, Mondello Isabella, Falcone Alessandra, Patti Maria Letizia, Boggini Tiziana, Bergamaschi Paola, Mozzetta Iolanda, Valentini Caterina Giovanna, Locatelli Emanuela, Albiani Roberto, Besso Federico Genzano, Cantone Giulia Vanina, Coscia Alessandra, Trimarchi Alfonso, Capone Anita, Ghirardello Stefano, Vento Giovanni, Teofili Luciana
Аннотация
STUDY DESIGN AND METHODS: The study illustrates CB-RBC concentrate production and inventory management across nine CB banks participating in the BORN trial. Quality requirements were those established by the European regulation for leukocyte-depleted RBC concentrates in additive solution. The compliance rate among centers was reported.
RESULTS: During the BORN study, 451 CB-RBC units were processed and 107 were transfused to 69 patients in the intervention arm. However, for 67 transfusion requests, no compatible CB-RBC units were available and adult-RBCs were given. The CB-RBC inventory comprised a minor fraction of CB units collected during the study period, suggesting that many did not meet the protocol-defined volume threshold of 67 mL at collection. Quality control results showed that 84.0% of units achieved target hematocrit (Htc) levels (50-70%), with higher success rates in centers processing more CB units. All centers met quality standards, maintaining residual leukocytes below 1 × 106 and end-storage hemolysis below 0.8% in more than 90% of cases. CB-RBC availability was significantly limited by the time required for bacterial testing results and the need for γ-irradiation.
DISCUSSION: These data suggest that the standardized CB-RBC production is reproducible. Moreover, extending CB-RBC storage to 21 days could maximize the inventory utility.